Analyst Ratings January 28, 2026

JPMorgan Lowers Coca-Cola FEMSA Rating to Neutral Citing Modest Growth Ahead

Bank trims outlook as Mexican volume headwinds and regional growth patterns shape 2026-27 forecasts

By Sofia Navarro KOF
JPMorgan Lowers Coca-Cola FEMSA Rating to Neutral Citing Modest Growth Ahead
KOF

JPMorgan has downgraded Coca-Cola FEMSA (KOF) from Overweight to Neutral and set a $100.00 price target, citing expectations of moderate consolidated growth through 2026 and 2027. The bank projects 5% top-line growth and 6% EBITDA growth for 2026, with a small margin expansion, while flagging a near-term decline in Mexican volumes linked to an excise tax pass-through. Barclays has issued a similar, cautious reassessment, lowering its rating to Equalweight with a $98.00 target.

Key Points

  • JPMorgan downgraded Coca-Cola FEMSA from Overweight to Neutral with a $100.00 price target while forecasting consolidated revenue growth of 5% and EBITDA growth of 6% in 2026.
  • The bank projects a 3% decline in Mexican volumes in 2026 due to the full pass-through of a flavored-drink excise tax, though Mexico and Central America revenues are still expected to rise 1.9% that year; a 6.5% volume rebound and 12% revenue increase are forecast for 2027 in the same region.
  • Barclays also trimmed its view, lowering its rating to Equalweight with a $98.00 target, but noted the company’s geographic diversification and hedging discipline as supports for earnings.

Overview

JPMorgan has reclassified Coca-Cola FEMSA (NYSE: KOF) from Overweight to Neutral and established a price target of $100.00. The move follows the bank's assessment that the company's consolidated growth will be modest over the next two years. At the time of the note, the stock was trading at $108.58, above JPMorgan's new target but described as undervalued by InvestingPro Fair Value metrics.

2026 financial outlook and operating assumptions

JPMorgan's 2026 forecast calls for consolidated revenue growth of 5% year-over-year and EBITDA growth of 6%, alongside a 20 basis point expansion in operating margins. The bank expects a 3% year-over-year decline in beverage volumes in Mexico for 2026, a drop it attributes to the full pass-through to consumers of a recent excise tax increase on flavored drinks. Even with the volume pressure, Mexico and Central America revenues are still projected to post 1.9% growth for 2026.

JPMorgan also notes that South America will remain an important contributor to consolidated results, with most markets in that region expected to show high single-digit growth in peso terms across both 2026 and 2027. However, the firm has trimmed its EBITDA estimates for 2026 slightly, citing slower growth momentum in South America.

2027 recovery assumptions

Looking to 2027, JPMorgan models a recovery in Mexican volumes, forecasting a 6.5% year-over-year increase that would bring volumes back to levels seen in 2024. The bank expects market share gains in Mexico and Central America to support a 12% revenue increase in that region in 2027, which helps underpin the projected improvement in consolidated results.

Market performance and financial health

Despite the downgrades from major brokers, Coca-Cola FEMSA has shown notable share-price momentum, delivering a 33% total return over the past six months. InvestingPro analysis attributes a "GREAT" financial health score to the company, a characterization referenced alongside the broker notes.

Other analyst action

Barclays has also moved to a more cautious stance, reducing its rating on Coca-Cola FEMSA from Overweight to Equalweight and setting a $98.00 price target. Barclays cited limited near-term upside potential but acknowledged the company’s geographic diversification and disciplined hedging strategies as ongoing supports for earnings strength.


Implications for investors

The broker revisions and the forecasts they contain offer a tempered view of near-term upside for Coca-Cola FEMSA. Market participants assessing the stock will want to weigh JPMorgan’s volume and margin assumptions for 2026 and the anticipated rebound in 2027 against the stock’s recent price performance and InvestingPro’s valuation and health metrics.

Risks

  • Mexican excise tax pass-through is expected to reduce volumes in Mexico by 3% in 2026, creating downside risk for near-term volume-driven revenue and margin metrics; this directly affects consumer staples exposure in Mexico and Central America.
  • Slower-than-anticipated growth in South America prompted a slight downward revision to JPMorgan’s 2026 EBITDA estimates, introducing execution and macro risks in South American markets that can influence consolidated earnings.
  • Analyst downgrades from multiple brokers highlight limited near-term upside potential, which could pressure investor sentiment and valuation multiples for the company’s equity in the short term.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026